PHAXIAM Therapeutics S.A. (PHXM.PA)
PHAXIAM Therapeutics S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Lyon, FR. The stock last traded at $0.10, up 0.00% on the session, giving a market capitalisation of $1.0M. Its beta of 1.74 implies it has historically moved more than the broad market.
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
PHAXIAM Therapeutics S.A. is most often compared with the following Healthcare names: